nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—lung cancer—testicular cancer	0.378	1	CtDrD
Crizotinib—STK10—testicular cancer	0.313	1	CbGaD
Crizotinib—AURKA—Epirubicin—testicular cancer	0.0864	0.548	CbGbCtD
Crizotinib—AURKA—Doxorubicin—testicular cancer	0.0459	0.291	CbGbCtD
Crizotinib—CYP3A5—Ifosfamide—testicular cancer	0.00588	0.0373	CbGbCtD
Crizotinib—ABCB1—Dactinomycin—testicular cancer	0.00324	0.0205	CbGbCtD
Crizotinib—CYP3A5—Etoposide—testicular cancer	0.00281	0.0178	CbGbCtD
Crizotinib—CYP3A4—Ifosfamide—testicular cancer	0.00229	0.0145	CbGbCtD
Crizotinib—ABCB1—Vinblastine—testicular cancer	0.00203	0.0129	CbGbCtD
Crizotinib—ABCB1—Cisplatin—testicular cancer	0.00186	0.0118	CbGbCtD
Crizotinib—ABCB1—Etoposide—testicular cancer	0.00183	0.0116	CbGbCtD
Crizotinib—ABCB1—Doxorubicin—testicular cancer	0.00125	0.00791	CbGbCtD
Crizotinib—CYP3A4—Vinblastine—testicular cancer	0.00122	0.00771	CbGbCtD
Crizotinib—ABCB1—Methotrexate—testicular cancer	0.00121	0.00766	CbGbCtD
Crizotinib—CYP3A4—Etoposide—testicular cancer	0.0011	0.00695	CbGbCtD
Crizotinib—CYP3A4—Doxorubicin—testicular cancer	0.000747	0.00474	CbGbCtD
Crizotinib—DSTYK—female gonad—testicular cancer	0.000314	0.00558	CbGeAlD
Crizotinib—CASK—female gonad—testicular cancer	0.000307	0.00545	CbGeAlD
Crizotinib—EPHA4—embryo—testicular cancer	0.000306	0.00544	CbGeAlD
Crizotinib—EPHA6—gonad—testicular cancer	0.000302	0.00537	CbGeAlD
Crizotinib—PLK4—gonad—testicular cancer	0.000298	0.0053	CbGeAlD
Crizotinib—RIPK2—seminal vesicle—testicular cancer	0.000298	0.00529	CbGeAlD
Crizotinib—MAPK7—female gonad—testicular cancer	0.000297	0.00528	CbGeAlD
Crizotinib—PRKD1—testis—testicular cancer	0.000297	0.00527	CbGeAlD
Crizotinib—PTK2—embryo—testicular cancer	0.000294	0.00523	CbGeAlD
Crizotinib—LIMK1—testis—testicular cancer	0.000293	0.0052	CbGeAlD
Crizotinib—PRKD3—testis—testicular cancer	0.000285	0.00507	CbGeAlD
Crizotinib—RPS6KB1—embryo—testicular cancer	0.000283	0.00503	CbGeAlD
Crizotinib—FGR—embryo—testicular cancer	0.000281	0.005	CbGeAlD
Crizotinib—FER—gonad—testicular cancer	0.00028	0.00498	CbGeAlD
Crizotinib—TYRO3—gonad—testicular cancer	0.00028	0.00498	CbGeAlD
Crizotinib—DSTYK—testis—testicular cancer	0.000279	0.00495	CbGeAlD
Crizotinib—MET—female gonad—testicular cancer	0.000278	0.00494	CbGeAlD
Crizotinib—TBK1—seminal vesicle—testicular cancer	0.000276	0.00491	CbGeAlD
Crizotinib—PTK2—seminal vesicle—testicular cancer	0.000276	0.00491	CbGeAlD
Crizotinib—TYK2—seminal vesicle—testicular cancer	0.000275	0.00488	CbGeAlD
Crizotinib—LTK—testis—testicular cancer	0.000272	0.00484	CbGeAlD
Crizotinib—CASK—testis—testicular cancer	0.000272	0.00484	CbGeAlD
Crizotinib—CDK7—female gonad—testicular cancer	0.000269	0.00478	CbGeAlD
Crizotinib—IGF1R—gonad—testicular cancer	0.000269	0.00478	CbGeAlD
Crizotinib—TAOK2—female gonad—testicular cancer	0.000267	0.00474	CbGeAlD
Crizotinib—JAK2—embryo—testicular cancer	0.000266	0.00473	CbGeAlD
Crizotinib—RPS6KB1—seminal vesicle—testicular cancer	0.000266	0.00472	CbGeAlD
Crizotinib—FGR—seminal vesicle—testicular cancer	0.000264	0.0047	CbGeAlD
Crizotinib—MAPK7—testis—testicular cancer	0.000264	0.00468	CbGeAlD
Crizotinib—TXK—testis—testicular cancer	0.000264	0.00468	CbGeAlD
Crizotinib—EPHA8—testis—testicular cancer	0.000261	0.00464	CbGeAlD
Crizotinib—FES—testis—testicular cancer	0.000261	0.00464	CbGeAlD
Crizotinib—ACVR1B—female gonad—testicular cancer	0.000257	0.00457	CbGeAlD
Crizotinib—TEK—embryo—testicular cancer	0.000256	0.00455	CbGeAlD
Crizotinib—AURKA—gonad—testicular cancer	0.000255	0.00453	CbGeAlD
Crizotinib—SLK—seminal vesicle—testicular cancer	0.000253	0.0045	CbGeAlD
Crizotinib—TESK1—gonad—testicular cancer	0.000253	0.0045	CbGeAlD
Crizotinib—EPHB4—seminal vesicle—testicular cancer	0.000252	0.00447	CbGeAlD
Crizotinib—JAK2—seminal vesicle—testicular cancer	0.00025	0.00444	CbGeAlD
Crizotinib—MET—testis—testicular cancer	0.000247	0.00439	CbGeAlD
Crizotinib—EPHA2—seminal vesicle—testicular cancer	0.000247	0.00439	CbGeAlD
Crizotinib—JAK3—female gonad—testicular cancer	0.000245	0.00436	CbGeAlD
Crizotinib—STK4—female gonad—testicular cancer	0.000241	0.00428	CbGeAlD
Crizotinib—MAP3K3—seminal vesicle—testicular cancer	0.000241	0.00428	CbGeAlD
Crizotinib—MAP4K5—seminal vesicle—testicular cancer	0.000241	0.00428	CbGeAlD
Crizotinib—LIMK2—gonad—testicular cancer	0.000241	0.00428	CbGeAlD
Crizotinib—CDK7—testis—testicular cancer	0.000239	0.00424	CbGeAlD
Crizotinib—MAP3K12—gonad—testicular cancer	0.000238	0.00423	CbGeAlD
Crizotinib—FLT3—gonad—testicular cancer	0.000238	0.00423	CbGeAlD
Crizotinib—TAOK2—testis—testicular cancer	0.000237	0.00421	CbGeAlD
Crizotinib—NEK9—lymph node—testicular cancer	0.000236	0.00419	CbGeAlD
Crizotinib—STK35—gonad—testicular cancer	0.000233	0.00415	CbGeAlD
Crizotinib—EPHB6—seminal vesicle—testicular cancer	0.00023	0.00409	CbGeAlD
Crizotinib—EPHA3—testis—testicular cancer	0.000228	0.00405	CbGeAlD
Crizotinib—ACVR1B—testis—testicular cancer	0.000228	0.00405	CbGeAlD
Crizotinib—SRC—embryo—testicular cancer	0.000228	0.00405	CbGeAlD
Crizotinib—FER—female gonad—testicular cancer	0.000228	0.00404	CbGeAlD
Crizotinib—TYRO3—female gonad—testicular cancer	0.000228	0.00404	CbGeAlD
Crizotinib—TNK1—female gonad—testicular cancer	0.000225	0.004	CbGeAlD
Crizotinib—BMP2K—gonad—testicular cancer	0.000225	0.00399	CbGeAlD
Crizotinib—BMPR1B—female gonad—testicular cancer	0.000223	0.00396	CbGeAlD
Crizotinib—YES1—seminal vesicle—testicular cancer	0.000222	0.00395	CbGeAlD
Crizotinib—TAOK3—seminal vesicle—testicular cancer	0.000219	0.0039	CbGeAlD
Crizotinib—TNK2—female gonad—testicular cancer	0.000219	0.00389	CbGeAlD
Crizotinib—IGF1R—female gonad—testicular cancer	0.000219	0.00389	CbGeAlD
Crizotinib—EPHA6—testis—testicular cancer	0.000218	0.00387	CbGeAlD
Crizotinib—JAK3—testis—testicular cancer	0.000218	0.00387	CbGeAlD
Crizotinib—PTK2B—gonad—testicular cancer	0.000217	0.00385	CbGeAlD
Crizotinib—CASK—Teniposide—Etoposide—testicular cancer	0.000216	0.117	CbGdCrCtD
Crizotinib—DCLK1—testis—testicular cancer	0.000216	0.00384	CbGeAlD
Crizotinib—MAP4K2—female gonad—testicular cancer	0.000216	0.00383	CbGeAlD
Crizotinib—PRKD1—lymph node—testicular cancer	0.000215	0.00382	CbGeAlD
Crizotinib—PLK4—testis—testicular cancer	0.000215	0.00382	CbGeAlD
Crizotinib—STK4—testis—testicular cancer	0.000214	0.0038	CbGeAlD
Crizotinib—STK3—female gonad—testicular cancer	0.000213	0.00378	CbGeAlD
Crizotinib—TIE1—female gonad—testicular cancer	0.000213	0.00378	CbGeAlD
Crizotinib—LIMK1—lymph node—testicular cancer	0.000212	0.00377	CbGeAlD
Crizotinib—EPHA4—gonad—testicular cancer	0.000208	0.0037	CbGeAlD
Crizotinib—AURKA—female gonad—testicular cancer	0.000207	0.00368	CbGeAlD
Crizotinib—PRKD3—lymph node—testicular cancer	0.000207	0.00368	CbGeAlD
Crizotinib—TESK1—female gonad—testicular cancer	0.000206	0.00365	CbGeAlD
Crizotinib—CSF1R—embryo—testicular cancer	0.000204	0.00363	CbGeAlD
Crizotinib—MAP3K2—gonad—testicular cancer	0.000204	0.00362	CbGeAlD
Crizotinib—FER—testis—testicular cancer	0.000202	0.00359	CbGeAlD
Crizotinib—TYRO3—testis—testicular cancer	0.000202	0.00359	CbGeAlD
Crizotinib—ALK—testis—testicular cancer	0.000202	0.00359	CbGeAlD
Crizotinib—DSTYK—lymph node—testicular cancer	0.000202	0.00359	CbGeAlD
Crizotinib—MERTK—female gonad—testicular cancer	0.0002	0.00355	CbGeAlD
Crizotinib—TNK1—testis—testicular cancer	0.0002	0.00355	CbGeAlD
Crizotinib—PTK2—gonad—testicular cancer	0.0002	0.00355	CbGeAlD
Crizotinib—TBK1—gonad—testicular cancer	0.0002	0.00355	CbGeAlD
Crizotinib—BLK—lymph node—testicular cancer	0.0002	0.00355	CbGeAlD
Crizotinib—MAP4K1—testis—testicular cancer	0.000198	0.00351	CbGeAlD
Crizotinib—MAP3K19—testis—testicular cancer	0.000198	0.00351	CbGeAlD
Crizotinib—BMPR1B—testis—testicular cancer	0.000198	0.00351	CbGeAlD
Crizotinib—LTK—lymph node—testicular cancer	0.000197	0.00351	CbGeAlD
Crizotinib—CASK—lymph node—testicular cancer	0.000197	0.00351	CbGeAlD
Crizotinib—LIMK2—female gonad—testicular cancer	0.000196	0.00348	CbGeAlD
Crizotinib—NUAK2—female gonad—testicular cancer	0.000195	0.00346	CbGeAlD
Crizotinib—TNK2—testis—testicular cancer	0.000194	0.00345	CbGeAlD
Crizotinib—IGF1R—testis—testicular cancer	0.000194	0.00345	CbGeAlD
Crizotinib—MAP3K12—female gonad—testicular cancer	0.000194	0.00344	CbGeAlD
Crizotinib—ACVR1—female gonad—testicular cancer	0.000194	0.00344	CbGeAlD
Crizotinib—FLT3—female gonad—testicular cancer	0.000194	0.00344	CbGeAlD
Crizotinib—CSF1R—seminal vesicle—testicular cancer	0.000192	0.00341	CbGeAlD
Crizotinib—MAP4K2—testis—testicular cancer	0.000191	0.0034	CbGeAlD
Crizotinib—MAPK7—lymph node—testicular cancer	0.000191	0.0034	CbGeAlD
Crizotinib—TXK—lymph node—testicular cancer	0.000191	0.0034	CbGeAlD
Crizotinib—AXL—gonad—testicular cancer	0.00019	0.00338	CbGeAlD
Crizotinib—STK35—female gonad—testicular cancer	0.00019	0.00337	CbGeAlD
Crizotinib—FES—lymph node—testicular cancer	0.000189	0.00336	CbGeAlD
Crizotinib—TIE1—testis—testicular cancer	0.000189	0.00335	CbGeAlD
Crizotinib—STK3—testis—testicular cancer	0.000189	0.00335	CbGeAlD
Crizotinib—ABL2—female gonad—testicular cancer	0.000185	0.00328	CbGeAlD
Crizotinib—AURKA—testis—testicular cancer	0.000184	0.00327	CbGeAlD
Crizotinib—BMP2K—female gonad—testicular cancer	0.000183	0.00324	CbGeAlD
Crizotinib—TESK1—testis—testicular cancer	0.000182	0.00324	CbGeAlD
Crizotinib—JAK2—gonad—testicular cancer	0.00018	0.00321	CbGeAlD
Crizotinib—MET—lymph node—testicular cancer	0.000179	0.00318	CbGeAlD
Crizotinib—MERTK—testis—testicular cancer	0.000177	0.00315	CbGeAlD
Crizotinib—PTK2B—female gonad—testicular cancer	0.000176	0.00313	CbGeAlD
Crizotinib—RIPK2—female gonad—testicular cancer	0.000175	0.00311	CbGeAlD
Crizotinib—MAP4K5—gonad—testicular cancer	0.000174	0.00309	CbGeAlD
Crizotinib—MAP3K3—gonad—testicular cancer	0.000174	0.00309	CbGeAlD
Crizotinib—LIMK2—testis—testicular cancer	0.000174	0.00308	CbGeAlD
Crizotinib—CDK7—lymph node—testicular cancer	0.000173	0.00307	CbGeAlD
Crizotinib—NUAK2—testis—testicular cancer	0.000173	0.00307	CbGeAlD
Crizotinib—MAP3K12—testis—testicular cancer	0.000172	0.00305	CbGeAlD
Crizotinib—FLT3—testis—testicular cancer	0.000172	0.00305	CbGeAlD
Crizotinib—ACVR1—testis—testicular cancer	0.000172	0.00305	CbGeAlD
Crizotinib—TAOK2—lymph node—testicular cancer	0.000172	0.00305	CbGeAlD
Crizotinib—EPHA4—female gonad—testicular cancer	0.000169	0.003	CbGeAlD
Crizotinib—STK35—testis—testicular cancer	0.000168	0.00299	CbGeAlD
Crizotinib—MAP3K2—female gonad—testicular cancer	0.000166	0.00295	CbGeAlD
Crizotinib—EPHA3—lymph node—testicular cancer	0.000165	0.00294	CbGeAlD
Crizotinib—ACVR1B—lymph node—testicular cancer	0.000165	0.00294	CbGeAlD
Crizotinib—ABL2—testis—testicular cancer	0.000164	0.00291	CbGeAlD
Crizotinib—PTK2—female gonad—testicular cancer	0.000162	0.00288	CbGeAlD
Crizotinib—TBK1—female gonad—testicular cancer	0.000162	0.00288	CbGeAlD
Crizotinib—BMP2K—testis—testicular cancer	0.000162	0.00288	CbGeAlD
Crizotinib—ABL1—embryo—testicular cancer	0.000162	0.00287	CbGeAlD
Crizotinib—TYK2—female gonad—testicular cancer	0.000161	0.00286	CbGeAlD
Crizotinib—YES1—gonad—testicular cancer	0.000161	0.00285	CbGeAlD
Crizotinib—STK10—gonad—testicular cancer	0.000159	0.00283	CbGeAlD
Crizotinib—IRAK1—female gonad—testicular cancer	0.000159	0.00283	CbGeAlD
Crizotinib—JAK3—lymph node—testicular cancer	0.000158	0.0028	CbGeAlD
Crizotinib—DCLK1—lymph node—testicular cancer	0.000157	0.00279	CbGeAlD
Crizotinib—PTK2B—testis—testicular cancer	0.000156	0.00278	CbGeAlD
Crizotinib—RPS6KB1—female gonad—testicular cancer	0.000156	0.00277	CbGeAlD
Crizotinib—PLK4—lymph node—testicular cancer	0.000156	0.00277	CbGeAlD
Crizotinib—LCK—female gonad—testicular cancer	0.000155	0.00276	CbGeAlD
Crizotinib—FGR—female gonad—testicular cancer	0.000155	0.00276	CbGeAlD
Crizotinib—RIPK2—testis—testicular cancer	0.000155	0.00276	CbGeAlD
Crizotinib—STK4—lymph node—testicular cancer	0.000155	0.00275	CbGeAlD
Crizotinib—AXL—female gonad—testicular cancer	0.000155	0.00275	CbGeAlD
Crizotinib—SRC—gonad—testicular cancer	0.000155	0.00275	CbGeAlD
Crizotinib—ABL1—seminal vesicle—testicular cancer	0.000152	0.0027	CbGeAlD
Crizotinib—EPHA4—testis—testicular cancer	0.00015	0.00266	CbGeAlD
Crizotinib—SLK—female gonad—testicular cancer	0.000149	0.00264	CbGeAlD
Crizotinib—EPHB4—female gonad—testicular cancer	0.000148	0.00262	CbGeAlD
Crizotinib—MAP3K2—testis—testicular cancer	0.000147	0.00261	CbGeAlD
Crizotinib—JAK2—female gonad—testicular cancer	0.000147	0.00261	CbGeAlD
Crizotinib—FER—lymph node—testicular cancer	0.000146	0.0026	CbGeAlD
Crizotinib—ALK—lymph node—testicular cancer	0.000146	0.0026	CbGeAlD
Crizotinib—EPHA2—female gonad—testicular cancer	0.000145	0.00258	CbGeAlD
Crizotinib—TNK1—lymph node—testicular cancer	0.000145	0.00257	CbGeAlD
Crizotinib—PTK2—testis—testicular cancer	0.000144	0.00256	CbGeAlD
Crizotinib—TBK1—testis—testicular cancer	0.000144	0.00256	CbGeAlD
Crizotinib—MAP4K1—lymph node—testicular cancer	0.000143	0.00255	CbGeAlD
Crizotinib—BMPR1B—lymph node—testicular cancer	0.000143	0.00255	CbGeAlD
Crizotinib—TYK2—testis—testicular cancer	0.000143	0.00254	CbGeAlD
Crizotinib—MAP4K5—female gonad—testicular cancer	0.000141	0.00251	CbGeAlD
Crizotinib—MAP3K3—female gonad—testicular cancer	0.000141	0.00251	CbGeAlD
Crizotinib—TEK—female gonad—testicular cancer	0.000141	0.00251	CbGeAlD
Crizotinib—IRAK1—testis—testicular cancer	0.000141	0.00251	CbGeAlD
Crizotinib—IGF1R—lymph node—testicular cancer	0.000141	0.0025	CbGeAlD
Crizotinib—TNK2—lymph node—testicular cancer	0.000141	0.0025	CbGeAlD
Crizotinib—CSF1R—gonad—testicular cancer	0.000139	0.00247	CbGeAlD
Crizotinib—MAP4K2—lymph node—testicular cancer	0.000139	0.00246	CbGeAlD
Crizotinib—RPS6KB1—testis—testicular cancer	0.000138	0.00246	CbGeAlD
Crizotinib—FGR—testis—testicular cancer	0.000138	0.00245	CbGeAlD
Crizotinib—LCK—testis—testicular cancer	0.000138	0.00245	CbGeAlD
Crizotinib—AXL—testis—testicular cancer	0.000137	0.00244	CbGeAlD
Crizotinib—STK3—lymph node—testicular cancer	0.000137	0.00243	CbGeAlD
Crizotinib—TIE1—lymph node—testicular cancer	0.000137	0.00243	CbGeAlD
Crizotinib—EPHB6—female gonad—testicular cancer	0.000135	0.0024	CbGeAlD
Crizotinib—AURKA—lymph node—testicular cancer	0.000133	0.00237	CbGeAlD
Crizotinib—TESK1—lymph node—testicular cancer	0.000132	0.00235	CbGeAlD
Crizotinib—SLK—testis—testicular cancer	0.000132	0.00234	CbGeAlD
Crizotinib—EPHB4—testis—testicular cancer	0.000131	0.00233	CbGeAlD
Crizotinib—YES1—female gonad—testicular cancer	0.000131	0.00232	CbGeAlD
Crizotinib—JAK2—testis—testicular cancer	0.00013	0.00231	CbGeAlD
Crizotinib—STK10—female gonad—testicular cancer	0.000129	0.0023	CbGeAlD
Crizotinib—TAOK3—female gonad—testicular cancer	0.000129	0.00229	CbGeAlD
Crizotinib—MERTK—lymph node—testicular cancer	0.000129	0.00228	CbGeAlD
Crizotinib—EPHA2—testis—testicular cancer	0.000129	0.00228	CbGeAlD
Crizotinib—LIMK2—lymph node—testicular cancer	0.000126	0.00223	CbGeAlD
Crizotinib—SRC—female gonad—testicular cancer	0.000126	0.00223	CbGeAlD
Crizotinib—TEK—testis—testicular cancer	0.000125	0.00223	CbGeAlD
Crizotinib—MAP3K3—testis—testicular cancer	0.000125	0.00223	CbGeAlD
Crizotinib—MAP4K5—testis—testicular cancer	0.000125	0.00223	CbGeAlD
Crizotinib—NUAK2—lymph node—testicular cancer	0.000125	0.00223	CbGeAlD
Crizotinib—MAP3K12—lymph node—testicular cancer	0.000124	0.00221	CbGeAlD
Crizotinib—FLT3—lymph node—testicular cancer	0.000124	0.00221	CbGeAlD
Crizotinib—ACVR1—lymph node—testicular cancer	0.000124	0.00221	CbGeAlD
Crizotinib—STK35—lymph node—testicular cancer	0.000122	0.00217	CbGeAlD
Crizotinib—EPHB6—testis—testicular cancer	0.00012	0.00213	CbGeAlD
Crizotinib—ABL2—lymph node—testicular cancer	0.000119	0.00211	CbGeAlD
Crizotinib—BMP2K—lymph node—testicular cancer	0.000117	0.00209	CbGeAlD
Crizotinib—YES1—testis—testicular cancer	0.000116	0.00206	CbGeAlD
Crizotinib—STK10—testis—testicular cancer	0.000115	0.00204	CbGeAlD
Crizotinib—TAOK3—testis—testicular cancer	0.000114	0.00203	CbGeAlD
Crizotinib—PTK2B—lymph node—testicular cancer	0.000113	0.00201	CbGeAlD
Crizotinib—CSF1R—female gonad—testicular cancer	0.000113	0.002	CbGeAlD
Crizotinib—RIPK2—lymph node—testicular cancer	0.000112	0.002	CbGeAlD
Crizotinib—SRC—testis—testicular cancer	0.000111	0.00198	CbGeAlD
Crizotinib—ABL1—gonad—testicular cancer	0.00011	0.00195	CbGeAlD
Crizotinib—EPHA4—lymph node—testicular cancer	0.000109	0.00193	CbGeAlD
Crizotinib—PLK4—Teniposide—Etoposide—testicular cancer	0.000107	0.058	CbGdCrCtD
Crizotinib—MAP3K2—lymph node—testicular cancer	0.000107	0.00189	CbGeAlD
Crizotinib—IGF1R—Idarubicin—Epirubicin—testicular cancer	0.000106	0.0576	CbGdCrCtD
Crizotinib—PTK2—lymph node—testicular cancer	0.000104	0.00185	CbGeAlD
Crizotinib—TBK1—lymph node—testicular cancer	0.000104	0.00185	CbGeAlD
Crizotinib—TYK2—lymph node—testicular cancer	0.000104	0.00184	CbGeAlD
Crizotinib—IRAK1—lymph node—testicular cancer	0.000102	0.00182	CbGeAlD
Crizotinib—RPS6KB1—lymph node—testicular cancer	0.0001	0.00178	CbGeAlD
Crizotinib—CSF1R—testis—testicular cancer	0.0001	0.00178	CbGeAlD
Crizotinib—LCK—lymph node—testicular cancer	9.98e-05	0.00177	CbGeAlD
Crizotinib—FGR—lymph node—testicular cancer	9.98e-05	0.00177	CbGeAlD
Crizotinib—AXL—lymph node—testicular cancer	9.94e-05	0.00177	CbGeAlD
Crizotinib—Anaemia—Ifosfamide—testicular cancer	9.89e-05	0.00225	CcSEcCtD
Crizotinib—Cardiac disorder—Cisplatin—testicular cancer	9.84e-05	0.00223	CcSEcCtD
Crizotinib—IGF1R—Idarubicin—Doxorubicin—testicular cancer	9.82e-05	0.0533	CbGdCrCtD
Crizotinib—Hypoaesthesia—Etoposide—testicular cancer	9.66e-05	0.00219	CcSEcCtD
Crizotinib—Urinary tract disorder—Etoposide—testicular cancer	9.59e-05	0.00218	CcSEcCtD
Crizotinib—Leukopenia—Ifosfamide—testicular cancer	9.58e-05	0.00218	CcSEcCtD
Crizotinib—SLK—lymph node—testicular cancer	9.57e-05	0.0017	CbGeAlD
Crizotinib—Mediastinal disorder—Cisplatin—testicular cancer	9.55e-05	0.00217	CcSEcCtD
Crizotinib—Oedema—Dactinomycin—testicular cancer	9.53e-05	0.00216	CcSEcCtD
Crizotinib—Fluid retention—Doxorubicin—testicular cancer	9.52e-05	0.00216	CcSEcCtD
Crizotinib—Urethral disorder—Etoposide—testicular cancer	9.52e-05	0.00216	CcSEcCtD
Crizotinib—EPHB4—lymph node—testicular cancer	9.5e-05	0.00169	CbGeAlD
Crizotinib—Asthenia—Chlorambucil—testicular cancer	9.48e-05	0.00215	CcSEcCtD
Crizotinib—Infection—Dactinomycin—testicular cancer	9.47e-05	0.00215	CcSEcCtD
Crizotinib—Arrhythmia—Cisplatin—testicular cancer	9.47e-05	0.00215	CcSEcCtD
Crizotinib—JAK2—lymph node—testicular cancer	9.43e-05	0.00168	CbGeAlD
Crizotinib—Neuropathy—Doxorubicin—testicular cancer	9.42e-05	0.00214	CcSEcCtD
Crizotinib—Sepsis—Epirubicin—testicular cancer	9.41e-05	0.00214	CcSEcCtD
Crizotinib—Hepatic failure—Methotrexate—testicular cancer	9.36e-05	0.00212	CcSEcCtD
Crizotinib—EPHA2—lymph node—testicular cancer	9.32e-05	0.00166	CbGeAlD
Crizotinib—Malnutrition—Cisplatin—testicular cancer	9.23e-05	0.0021	CcSEcCtD
Crizotinib—Paraesthesia—Bleomycin—testicular cancer	9.18e-05	0.00208	CcSEcCtD
Crizotinib—Dyspnoea—Bleomycin—testicular cancer	9.11e-05	0.00207	CcSEcCtD
Crizotinib—MAP4K5—lymph node—testicular cancer	9.09e-05	0.00162	CbGeAlD
Crizotinib—TEK—lymph node—testicular cancer	9.09e-05	0.00162	CbGeAlD
Crizotinib—MAP3K3—lymph node—testicular cancer	9.09e-05	0.00162	CbGeAlD
Crizotinib—Eye disorder—Etoposide—testicular cancer	9.08e-05	0.00206	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	9.05e-05	0.00206	CcSEcCtD
Crizotinib—Blood alkaline phosphatase increased—Epirubicin—testicular cancer	9.05e-05	0.00205	CcSEcCtD
Crizotinib—Diarrhoea—Chlorambucil—testicular cancer	9.04e-05	0.00205	CcSEcCtD
Crizotinib—Cardiac disorder—Etoposide—testicular cancer	9.01e-05	0.00205	CcSEcCtD
Crizotinib—Hepatic function abnormal—Epirubicin—testicular cancer	9e-05	0.00204	CcSEcCtD
Crizotinib—ABL1—female gonad—testicular cancer	8.91e-05	0.00158	CbGeAlD
Crizotinib—Decreased appetite—Bleomycin—testicular cancer	8.89e-05	0.00202	CcSEcCtD
Crizotinib—Visual disturbance—Methotrexate—testicular cancer	8.87e-05	0.00201	CcSEcCtD
Crizotinib—Hepatic failure—Epirubicin—testicular cancer	8.76e-05	0.00199	CcSEcCtD
Crizotinib—Mediastinal disorder—Etoposide—testicular cancer	8.75e-05	0.00199	CcSEcCtD
Crizotinib—Oedema—Ifosfamide—testicular cancer	8.74e-05	0.00198	CcSEcCtD
Crizotinib—Sepsis—Doxorubicin—testicular cancer	8.7e-05	0.00198	CcSEcCtD
Crizotinib—Vision blurred—Cisplatin—testicular cancer	8.7e-05	0.00197	CcSEcCtD
Crizotinib—EPHB6—lymph node—testicular cancer	8.69e-05	0.00154	CbGeAlD
Crizotinib—Asthenia—Vinblastine—testicular cancer	8.68e-05	0.00197	CcSEcCtD
Crizotinib—Infection—Ifosfamide—testicular cancer	8.68e-05	0.00197	CcSEcCtD
Crizotinib—Nervous system disorder—Ifosfamide—testicular cancer	8.57e-05	0.00195	CcSEcCtD
Crizotinib—CDK7—Daunorubicin—Epirubicin—testicular cancer	8.56e-05	0.0464	CbGdCrCtD
Crizotinib—CDK7—Doxorubicin—Epirubicin—testicular cancer	8.56e-05	0.0464	CbGdCrCtD
Crizotinib—CDK7—Idarubicin—Epirubicin—testicular cancer	8.56e-05	0.0464	CbGdCrCtD
Crizotinib—Anaemia—Cisplatin—testicular cancer	8.53e-05	0.00194	CcSEcCtD
Crizotinib—Skin disorder—Ifosfamide—testicular cancer	8.48e-05	0.00193	CcSEcCtD
Crizotinib—Vomiting—Chlorambucil—testicular cancer	8.4e-05	0.00191	CcSEcCtD
Crizotinib—YES1—lymph node—testicular cancer	8.39e-05	0.00149	CbGeAlD
Crizotinib—AURKA—Teniposide—Etoposide—testicular cancer	8.37e-05	0.0454	CbGdCrCtD
Crizotinib—Blood alkaline phosphatase increased—Doxorubicin—testicular cancer	8.37e-05	0.0019	CcSEcCtD
Crizotinib—Hepatic function abnormal—Doxorubicin—testicular cancer	8.33e-05	0.00189	CcSEcCtD
Crizotinib—STK10—lymph node—testicular cancer	8.32e-05	0.00148	CbGeAlD
Crizotinib—Decreased appetite—Dactinomycin—testicular cancer	8.29e-05	0.00188	CcSEcCtD
Crizotinib—TAOK3—lymph node—testicular cancer	8.29e-05	0.00147	CbGeAlD
Crizotinib—Diarrhoea—Vinblastine—testicular cancer	8.28e-05	0.00188	CcSEcCtD
Crizotinib—Dysgeusia—Etoposide—testicular cancer	8.28e-05	0.00188	CcSEcCtD
Crizotinib—Leukopenia—Cisplatin—testicular cancer	8.26e-05	0.00188	CcSEcCtD
Crizotinib—Fatigue—Dactinomycin—testicular cancer	8.22e-05	0.00187	CcSEcCtD
Crizotinib—Hepatic failure—Doxorubicin—testicular cancer	8.1e-05	0.00184	CcSEcCtD
Crizotinib—Body temperature increased—Bleomycin—testicular cancer	8.08e-05	0.00183	CcSEcCtD
Crizotinib—SRC—lymph node—testicular cancer	8.08e-05	0.00143	CbGeAlD
Crizotinib—Dizziness—Vinblastine—testicular cancer	8e-05	0.00182	CcSEcCtD
Crizotinib—CDK7—Idarubicin—Doxorubicin—testicular cancer	7.92e-05	0.0429	CbGdCrCtD
Crizotinib—CDK7—Epirubicin—Doxorubicin—testicular cancer	7.92e-05	0.0429	CbGdCrCtD
Crizotinib—CDK7—Daunorubicin—Doxorubicin—testicular cancer	7.92e-05	0.0429	CbGdCrCtD
Crizotinib—ABL1—testis—testicular cancer	7.91e-05	0.0014	CbGeAlD
Crizotinib—Diplopia—Epirubicin—testicular cancer	7.87e-05	0.00179	CcSEcCtD
Crizotinib—Nausea—Chlorambucil—testicular cancer	7.84e-05	0.00178	CcSEcCtD
Crizotinib—Paraesthesia—Ifosfamide—testicular cancer	7.84e-05	0.00178	CcSEcCtD
Crizotinib—Anaemia—Etoposide—testicular cancer	7.81e-05	0.00177	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	7.8e-05	0.00177	CcSEcCtD
Crizotinib—Dyspnoea—Ifosfamide—testicular cancer	7.79e-05	0.00177	CcSEcCtD
Crizotinib—Vomiting—Vinblastine—testicular cancer	7.69e-05	0.00175	CcSEcCtD
Crizotinib—Face oedema—Epirubicin—testicular cancer	7.6e-05	0.00173	CcSEcCtD
Crizotinib—Decreased appetite—Ifosfamide—testicular cancer	7.59e-05	0.00172	CcSEcCtD
Crizotinib—Leukopenia—Etoposide—testicular cancer	7.57e-05	0.00172	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Ifosfamide—testicular cancer	7.54e-05	0.00171	CcSEcCtD
Crizotinib—Body temperature increased—Dactinomycin—testicular cancer	7.54e-05	0.00171	CcSEcCtD
Crizotinib—Fatigue—Ifosfamide—testicular cancer	7.53e-05	0.00171	CcSEcCtD
Crizotinib—Oedema—Cisplatin—testicular cancer	7.53e-05	0.00171	CcSEcCtD
Crizotinib—Infection—Cisplatin—testicular cancer	7.48e-05	0.0017	CcSEcCtD
Crizotinib—Constipation—Ifosfamide—testicular cancer	7.47e-05	0.0017	CcSEcCtD
Crizotinib—Loss of consciousness—Etoposide—testicular cancer	7.43e-05	0.00169	CcSEcCtD
Crizotinib—Nervous system disorder—Cisplatin—testicular cancer	7.39e-05	0.00168	CcSEcCtD
Crizotinib—Asthenia—Bleomycin—testicular cancer	7.33e-05	0.00167	CcSEcCtD
Crizotinib—Skin disorder—Cisplatin—testicular cancer	7.31e-05	0.00166	CcSEcCtD
Crizotinib—Diplopia—Doxorubicin—testicular cancer	7.28e-05	0.00165	CcSEcCtD
Crizotinib—CSF1R—lymph node—testicular cancer	7.25e-05	0.00129	CbGeAlD
Crizotinib—Nausea—Vinblastine—testicular cancer	7.19e-05	0.00163	CcSEcCtD
Crizotinib—Hypokalaemia—Epirubicin—testicular cancer	7.16e-05	0.00163	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	7.15e-05	0.00162	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Epirubicin—testicular cancer	7.09e-05	0.00161	CcSEcCtD
Crizotinib—Face oedema—Doxorubicin—testicular cancer	7.03e-05	0.0016	CcSEcCtD
Crizotinib—Muscular weakness—Epirubicin—testicular cancer	6.94e-05	0.00158	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Epirubicin—testicular cancer	6.94e-05	0.00158	CcSEcCtD
Crizotinib—Body temperature increased—Ifosfamide—testicular cancer	6.91e-05	0.00157	CcSEcCtD
Crizotinib—Infection—Etoposide—testicular cancer	6.85e-05	0.00156	CcSEcCtD
Crizotinib—Asthenia—Dactinomycin—testicular cancer	6.84e-05	0.00155	CcSEcCtD
Crizotinib—Neutropenia—Methotrexate—testicular cancer	6.8e-05	0.00154	CcSEcCtD
Crizotinib—Paraesthesia—Cisplatin—testicular cancer	6.76e-05	0.00154	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Methotrexate—testicular cancer	6.75e-05	0.00153	CcSEcCtD
Crizotinib—Dyspnoea—Cisplatin—testicular cancer	6.71e-05	0.00152	CcSEcCtD
Crizotinib—Skin disorder—Etoposide—testicular cancer	6.7e-05	0.00152	CcSEcCtD
Crizotinib—Hypokalaemia—Doxorubicin—testicular cancer	6.63e-05	0.0015	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	6.56e-05	0.00149	CcSEcCtD
Crizotinib—Decreased appetite—Cisplatin—testicular cancer	6.55e-05	0.00149	CcSEcCtD
Crizotinib—Diarrhoea—Dactinomycin—testicular cancer	6.52e-05	0.00148	CcSEcCtD
Crizotinib—Pneumonia—Methotrexate—testicular cancer	6.52e-05	0.00148	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Cisplatin—testicular cancer	6.5e-05	0.00148	CcSEcCtD
Crizotinib—Vomiting—Bleomycin—testicular cancer	6.5e-05	0.00148	CcSEcCtD
Crizotinib—Infestation NOS—Methotrexate—testicular cancer	6.48e-05	0.00147	CcSEcCtD
Crizotinib—Infestation—Methotrexate—testicular cancer	6.48e-05	0.00147	CcSEcCtD
Crizotinib—Rash—Bleomycin—testicular cancer	6.44e-05	0.00146	CcSEcCtD
Crizotinib—Dermatitis—Bleomycin—testicular cancer	6.44e-05	0.00146	CcSEcCtD
Crizotinib—Muscular weakness—Doxorubicin—testicular cancer	6.42e-05	0.00146	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Doxorubicin—testicular cancer	6.42e-05	0.00146	CcSEcCtD
Crizotinib—Neutropenia—Epirubicin—testicular cancer	6.36e-05	0.00144	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Epirubicin—testicular cancer	6.32e-05	0.00144	CcSEcCtD
Crizotinib—Asthenia—Ifosfamide—testicular cancer	6.27e-05	0.00142	CcSEcCtD
Crizotinib—Paraesthesia—Etoposide—testicular cancer	6.2e-05	0.00141	CcSEcCtD
Crizotinib—Weight decreased—Epirubicin—testicular cancer	6.15e-05	0.0014	CcSEcCtD
Crizotinib—Dyspnoea—Etoposide—testicular cancer	6.15e-05	0.0014	CcSEcCtD
Crizotinib—Hepatobiliary disease—Methotrexate—testicular cancer	6.13e-05	0.00139	CcSEcCtD
Crizotinib—Pneumonia—Epirubicin—testicular cancer	6.1e-05	0.00139	CcSEcCtD
Crizotinib—Nausea—Bleomycin—testicular cancer	6.07e-05	0.00138	CcSEcCtD
Crizotinib—Infestation NOS—Epirubicin—testicular cancer	6.06e-05	0.00138	CcSEcCtD
Crizotinib—Infestation—Epirubicin—testicular cancer	6.06e-05	0.00138	CcSEcCtD
Crizotinib—Vomiting—Dactinomycin—testicular cancer	6.06e-05	0.00138	CcSEcCtD
Crizotinib—Rash—Dactinomycin—testicular cancer	6.01e-05	0.00136	CcSEcCtD
Crizotinib—Decreased appetite—Etoposide—testicular cancer	6e-05	0.00136	CcSEcCtD
Crizotinib—Diarrhoea—Ifosfamide—testicular cancer	5.98e-05	0.00136	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Etoposide—testicular cancer	5.96e-05	0.00135	CcSEcCtD
Crizotinib—Body temperature increased—Cisplatin—testicular cancer	5.95e-05	0.00135	CcSEcCtD
Crizotinib—Fatigue—Etoposide—testicular cancer	5.95e-05	0.00135	CcSEcCtD
Crizotinib—Neuropathy peripheral—Epirubicin—testicular cancer	5.94e-05	0.00135	CcSEcCtD
Crizotinib—Constipation—Etoposide—testicular cancer	5.9e-05	0.00134	CcSEcCtD
Crizotinib—Neutropenia—Doxorubicin—testicular cancer	5.88e-05	0.00134	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Doxorubicin—testicular cancer	5.85e-05	0.00133	CcSEcCtD
Crizotinib—Dizziness—Ifosfamide—testicular cancer	5.78e-05	0.00131	CcSEcCtD
Crizotinib—Urinary tract disorder—Methotrexate—testicular cancer	5.74e-05	0.0013	CcSEcCtD
Crizotinib—Hepatobiliary disease—Epirubicin—testicular cancer	5.73e-05	0.0013	CcSEcCtD
Crizotinib—ABL1—lymph node—testicular cancer	5.73e-05	0.00102	CbGeAlD
Crizotinib—Urethral disorder—Methotrexate—testicular cancer	5.7e-05	0.00129	CcSEcCtD
Crizotinib—Weight decreased—Doxorubicin—testicular cancer	5.69e-05	0.00129	CcSEcCtD
Crizotinib—Nausea—Dactinomycin—testicular cancer	5.66e-05	0.00129	CcSEcCtD
Crizotinib—Pneumonia—Doxorubicin—testicular cancer	5.64e-05	0.00128	CcSEcCtD
Crizotinib—Infestation—Doxorubicin—testicular cancer	5.61e-05	0.00127	CcSEcCtD
Crizotinib—Infestation NOS—Doxorubicin—testicular cancer	5.61e-05	0.00127	CcSEcCtD
Crizotinib—Visual impairment—Methotrexate—testicular cancer	5.61e-05	0.00127	CcSEcCtD
Crizotinib—PLK4—Idarubicin—Epirubicin—testicular cancer	5.58e-05	0.0302	CbGdCrCtD
Crizotinib—PLK4—Doxorubicin—Epirubicin—testicular cancer	5.58e-05	0.0302	CbGdCrCtD
Crizotinib—Vomiting—Ifosfamide—testicular cancer	5.55e-05	0.00126	CcSEcCtD
Crizotinib—Bradycardia—Epirubicin—testicular cancer	5.54e-05	0.00126	CcSEcCtD
Crizotinib—Rash—Ifosfamide—testicular cancer	5.51e-05	0.00125	CcSEcCtD
Crizotinib—Dermatitis—Ifosfamide—testicular cancer	5.5e-05	0.00125	CcSEcCtD
Crizotinib—Neuropathy peripheral—Doxorubicin—testicular cancer	5.5e-05	0.00125	CcSEcCtD
Crizotinib—Body temperature increased—Etoposide—testicular cancer	5.45e-05	0.00124	CcSEcCtD
Crizotinib—Eye disorder—Methotrexate—testicular cancer	5.44e-05	0.00123	CcSEcCtD
Crizotinib—Hypoaesthesia—Epirubicin—testicular cancer	5.42e-05	0.00123	CcSEcCtD
Crizotinib—Asthenia—Cisplatin—testicular cancer	5.4e-05	0.00123	CcSEcCtD
Crizotinib—Cardiac disorder—Methotrexate—testicular cancer	5.4e-05	0.00123	CcSEcCtD
Crizotinib—Urinary tract disorder—Epirubicin—testicular cancer	5.38e-05	0.00122	CcSEcCtD
Crizotinib—Oedema peripheral—Epirubicin—testicular cancer	5.36e-05	0.00122	CcSEcCtD
Crizotinib—Urethral disorder—Epirubicin—testicular cancer	5.34e-05	0.00121	CcSEcCtD
Crizotinib—Hepatobiliary disease—Doxorubicin—testicular cancer	5.31e-05	0.0012	CcSEcCtD
Crizotinib—Visual impairment—Epirubicin—testicular cancer	5.25e-05	0.00119	CcSEcCtD
Crizotinib—Mediastinal disorder—Methotrexate—testicular cancer	5.24e-05	0.00119	CcSEcCtD
Crizotinib—CYP3A5—female gonad—testicular cancer	5.22e-05	0.000927	CbGeAlD
Crizotinib—Nausea—Ifosfamide—testicular cancer	5.19e-05	0.00118	CcSEcCtD
Crizotinib—PLK4—Idarubicin—Doxorubicin—testicular cancer	5.16e-05	0.028	CbGdCrCtD
Crizotinib—PLK4—Epirubicin—Doxorubicin—testicular cancer	5.16e-05	0.028	CbGdCrCtD
Crizotinib—Diarrhoea—Cisplatin—testicular cancer	5.15e-05	0.00117	CcSEcCtD
Crizotinib—Bradycardia—Doxorubicin—testicular cancer	5.13e-05	0.00116	CcSEcCtD
Crizotinib—Eye disorder—Epirubicin—testicular cancer	5.09e-05	0.00116	CcSEcCtD
Crizotinib—Malnutrition—Methotrexate—testicular cancer	5.06e-05	0.00115	CcSEcCtD
Crizotinib—Cardiac disorder—Epirubicin—testicular cancer	5.05e-05	0.00115	CcSEcCtD
Crizotinib—ABCB1—embryo—testicular cancer	5.03e-05	0.000893	CbGeAlD
Crizotinib—Hypoaesthesia—Doxorubicin—testicular cancer	5.01e-05	0.00114	CcSEcCtD
Crizotinib—Urinary tract disorder—Doxorubicin—testicular cancer	4.97e-05	0.00113	CcSEcCtD
Crizotinib—Oedema peripheral—Doxorubicin—testicular cancer	4.96e-05	0.00113	CcSEcCtD
Crizotinib—Dysgeusia—Methotrexate—testicular cancer	4.96e-05	0.00113	CcSEcCtD
Crizotinib—Asthenia—Etoposide—testicular cancer	4.95e-05	0.00112	CcSEcCtD
Crizotinib—Urethral disorder—Doxorubicin—testicular cancer	4.94e-05	0.00112	CcSEcCtD
Crizotinib—Mediastinal disorder—Epirubicin—testicular cancer	4.91e-05	0.00111	CcSEcCtD
Crizotinib—Arrhythmia—Epirubicin—testicular cancer	4.86e-05	0.0011	CcSEcCtD
Crizotinib—Visual impairment—Doxorubicin—testicular cancer	4.85e-05	0.0011	CcSEcCtD
Crizotinib—Vomiting—Cisplatin—testicular cancer	4.79e-05	0.00109	CcSEcCtD
Crizotinib—Vision blurred—Methotrexate—testicular cancer	4.77e-05	0.00108	CcSEcCtD
Crizotinib—Rash—Cisplatin—testicular cancer	4.75e-05	0.00108	CcSEcCtD
Crizotinib—Dermatitis—Cisplatin—testicular cancer	4.74e-05	0.00108	CcSEcCtD
Crizotinib—Malnutrition—Epirubicin—testicular cancer	4.74e-05	0.00108	CcSEcCtD
Crizotinib—Diarrhoea—Etoposide—testicular cancer	4.72e-05	0.00107	CcSEcCtD
Crizotinib—ABCB1—seminal vesicle—testicular cancer	4.72e-05	0.000839	CbGeAlD
Crizotinib—Eye disorder—Doxorubicin—testicular cancer	4.71e-05	0.00107	CcSEcCtD
Crizotinib—ABL1—Idarubicin—Epirubicin—testicular cancer	4.69e-05	0.0254	CbGdCrCtD
Crizotinib—ABL1—Daunorubicin—Epirubicin—testicular cancer	4.69e-05	0.0254	CbGdCrCtD
Crizotinib—ABL1—Doxorubicin—Epirubicin—testicular cancer	4.69e-05	0.0254	CbGdCrCtD
Crizotinib—Anaemia—Methotrexate—testicular cancer	4.68e-05	0.00106	CcSEcCtD
Crizotinib—Cardiac disorder—Doxorubicin—testicular cancer	4.67e-05	0.00106	CcSEcCtD
Crizotinib—Dysgeusia—Epirubicin—testicular cancer	4.64e-05	0.00105	CcSEcCtD
Crizotinib—Dizziness—Etoposide—testicular cancer	4.56e-05	0.00104	CcSEcCtD
Crizotinib—Mediastinal disorder—Doxorubicin—testicular cancer	4.54e-05	0.00103	CcSEcCtD
Crizotinib—Leukopenia—Methotrexate—testicular cancer	4.53e-05	0.00103	CcSEcCtD
Crizotinib—Arrhythmia—Doxorubicin—testicular cancer	4.5e-05	0.00102	CcSEcCtD
Crizotinib—Nausea—Cisplatin—testicular cancer	4.47e-05	0.00102	CcSEcCtD
Crizotinib—Vision blurred—Epirubicin—testicular cancer	4.47e-05	0.00101	CcSEcCtD
Crizotinib—Vomiting—Etoposide—testicular cancer	4.39e-05	0.000996	CcSEcCtD
Crizotinib—Malnutrition—Doxorubicin—testicular cancer	4.38e-05	0.000996	CcSEcCtD
Crizotinib—Anaemia—Epirubicin—testicular cancer	4.38e-05	0.000995	CcSEcCtD
Crizotinib—AURKA—Doxorubicin—Epirubicin—testicular cancer	4.37e-05	0.0237	CbGdCrCtD
Crizotinib—AURKA—Daunorubicin—Epirubicin—testicular cancer	4.37e-05	0.0237	CbGdCrCtD
Crizotinib—AURKA—Idarubicin—Epirubicin—testicular cancer	4.37e-05	0.0237	CbGdCrCtD
Crizotinib—Rash—Etoposide—testicular cancer	4.35e-05	0.000988	CcSEcCtD
Crizotinib—Dermatitis—Etoposide—testicular cancer	4.35e-05	0.000987	CcSEcCtD
Crizotinib—ABL1—Idarubicin—Doxorubicin—testicular cancer	4.34e-05	0.0235	CbGdCrCtD
Crizotinib—ABL1—Epirubicin—Doxorubicin—testicular cancer	4.34e-05	0.0235	CbGdCrCtD
Crizotinib—ABL1—Daunorubicin—Doxorubicin—testicular cancer	4.34e-05	0.0235	CbGdCrCtD
Crizotinib—Dysgeusia—Doxorubicin—testicular cancer	4.29e-05	0.000975	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	4.28e-05	0.000972	CcSEcCtD
Crizotinib—Syncope—Epirubicin—testicular cancer	4.25e-05	0.000965	CcSEcCtD
Crizotinib—Leukopenia—Epirubicin—testicular cancer	4.24e-05	0.000963	CcSEcCtD
Crizotinib—Loss of consciousness—Epirubicin—testicular cancer	4.16e-05	0.000946	CcSEcCtD
Crizotinib—Vision blurred—Doxorubicin—testicular cancer	4.13e-05	0.000938	CcSEcCtD
Crizotinib—Infection—Methotrexate—testicular cancer	4.11e-05	0.000932	CcSEcCtD
Crizotinib—Nausea—Etoposide—testicular cancer	4.1e-05	0.000931	CcSEcCtD
Crizotinib—Nervous system disorder—Methotrexate—testicular cancer	4.05e-05	0.00092	CcSEcCtD
Crizotinib—Anaemia—Doxorubicin—testicular cancer	4.05e-05	0.00092	CcSEcCtD
Crizotinib—AURKA—Idarubicin—Doxorubicin—testicular cancer	4.04e-05	0.0219	CbGdCrCtD
Crizotinib—AURKA—Daunorubicin—Doxorubicin—testicular cancer	4.04e-05	0.0219	CbGdCrCtD
Crizotinib—AURKA—Epirubicin—Doxorubicin—testicular cancer	4.04e-05	0.0219	CbGdCrCtD
Crizotinib—Skin disorder—Methotrexate—testicular cancer	4.01e-05	0.000912	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	4.01e-05	0.00091	CcSEcCtD
Crizotinib—Syncope—Doxorubicin—testicular cancer	3.93e-05	0.000893	CcSEcCtD
Crizotinib—Leukopenia—Doxorubicin—testicular cancer	3.92e-05	0.000891	CcSEcCtD
Crizotinib—Oedema—Epirubicin—testicular cancer	3.87e-05	0.000878	CcSEcCtD
Crizotinib—Loss of consciousness—Doxorubicin—testicular cancer	3.85e-05	0.000875	CcSEcCtD
Crizotinib—Infection—Epirubicin—testicular cancer	3.84e-05	0.000872	CcSEcCtD
Crizotinib—Shock—Epirubicin—testicular cancer	3.8e-05	0.000864	CcSEcCtD
Crizotinib—Nervous system disorder—Epirubicin—testicular cancer	3.79e-05	0.000861	CcSEcCtD
Crizotinib—Skin disorder—Epirubicin—testicular cancer	3.76e-05	0.000853	CcSEcCtD
Crizotinib—Paraesthesia—Methotrexate—testicular cancer	3.71e-05	0.000843	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	3.71e-05	0.000842	CcSEcCtD
Crizotinib—Dyspnoea—Methotrexate—testicular cancer	3.68e-05	0.000837	CcSEcCtD
Crizotinib—Dyspepsia—Methotrexate—testicular cancer	3.64e-05	0.000826	CcSEcCtD
Crizotinib—Decreased appetite—Methotrexate—testicular cancer	3.59e-05	0.000816	CcSEcCtD
Crizotinib—Oedema—Doxorubicin—testicular cancer	3.58e-05	0.000813	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Methotrexate—testicular cancer	3.57e-05	0.00081	CcSEcCtD
Crizotinib—Fatigue—Methotrexate—testicular cancer	3.56e-05	0.000809	CcSEcCtD
Crizotinib—Infection—Doxorubicin—testicular cancer	3.55e-05	0.000807	CcSEcCtD
Crizotinib—Shock—Doxorubicin—testicular cancer	3.52e-05	0.000799	CcSEcCtD
Crizotinib—Nervous system disorder—Doxorubicin—testicular cancer	3.51e-05	0.000797	CcSEcCtD
Crizotinib—Skin disorder—Doxorubicin—testicular cancer	3.48e-05	0.000789	CcSEcCtD
Crizotinib—Paraesthesia—Epirubicin—testicular cancer	3.47e-05	0.000789	CcSEcCtD
Crizotinib—Dyspnoea—Epirubicin—testicular cancer	3.45e-05	0.000783	CcSEcCtD
Crizotinib—ABCB1—gonad—testicular cancer	3.41e-05	0.000606	CbGeAlD
Crizotinib—Dyspepsia—Epirubicin—testicular cancer	3.4e-05	0.000773	CcSEcCtD
Crizotinib—Decreased appetite—Epirubicin—testicular cancer	3.36e-05	0.000763	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Epirubicin—testicular cancer	3.34e-05	0.000758	CcSEcCtD
Crizotinib—Fatigue—Epirubicin—testicular cancer	3.33e-05	0.000757	CcSEcCtD
Crizotinib—Constipation—Epirubicin—testicular cancer	3.31e-05	0.000751	CcSEcCtD
Crizotinib—Body temperature increased—Methotrexate—testicular cancer	3.27e-05	0.000742	CcSEcCtD
Crizotinib—Paraesthesia—Doxorubicin—testicular cancer	3.21e-05	0.00073	CcSEcCtD
Crizotinib—Dyspnoea—Doxorubicin—testicular cancer	3.19e-05	0.000724	CcSEcCtD
Crizotinib—Dyspepsia—Doxorubicin—testicular cancer	3.15e-05	0.000715	CcSEcCtD
Crizotinib—Decreased appetite—Doxorubicin—testicular cancer	3.11e-05	0.000706	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Doxorubicin—testicular cancer	3.09e-05	0.000702	CcSEcCtD
Crizotinib—Fatigue—Doxorubicin—testicular cancer	3.09e-05	0.000701	CcSEcCtD
Crizotinib—Constipation—Doxorubicin—testicular cancer	3.06e-05	0.000695	CcSEcCtD
Crizotinib—Body temperature increased—Epirubicin—testicular cancer	3.06e-05	0.000694	CcSEcCtD
Crizotinib—Asthenia—Methotrexate—testicular cancer	2.96e-05	0.000673	CcSEcCtD
Crizotinib—Body temperature increased—Doxorubicin—testicular cancer	2.83e-05	0.000642	CcSEcCtD
Crizotinib—Diarrhoea—Methotrexate—testicular cancer	2.83e-05	0.000642	CcSEcCtD
Crizotinib—Asthenia—Epirubicin—testicular cancer	2.77e-05	0.00063	CcSEcCtD
Crizotinib—ABCB1—female gonad—testicular cancer	2.77e-05	0.000493	CbGeAlD
Crizotinib—Dizziness—Methotrexate—testicular cancer	2.73e-05	0.000621	CcSEcCtD
Crizotinib—Diarrhoea—Epirubicin—testicular cancer	2.65e-05	0.000601	CcSEcCtD
Crizotinib—Vomiting—Methotrexate—testicular cancer	2.63e-05	0.000597	CcSEcCtD
Crizotinib—Rash—Methotrexate—testicular cancer	2.61e-05	0.000592	CcSEcCtD
Crizotinib—Dermatitis—Methotrexate—testicular cancer	2.6e-05	0.000591	CcSEcCtD
Crizotinib—Asthenia—Doxorubicin—testicular cancer	2.57e-05	0.000583	CcSEcCtD
Crizotinib—Dizziness—Epirubicin—testicular cancer	2.56e-05	0.000581	CcSEcCtD
Crizotinib—Vomiting—Epirubicin—testicular cancer	2.46e-05	0.000558	CcSEcCtD
Crizotinib—ABCB1—testis—testicular cancer	2.46e-05	0.000437	CbGeAlD
Crizotinib—Nausea—Methotrexate—testicular cancer	2.45e-05	0.000557	CcSEcCtD
Crizotinib—Diarrhoea—Doxorubicin—testicular cancer	2.45e-05	0.000556	CcSEcCtD
Crizotinib—Rash—Epirubicin—testicular cancer	2.44e-05	0.000554	CcSEcCtD
Crizotinib—Dermatitis—Epirubicin—testicular cancer	2.44e-05	0.000553	CcSEcCtD
Crizotinib—Dizziness—Doxorubicin—testicular cancer	2.37e-05	0.000537	CcSEcCtD
Crizotinib—Nausea—Epirubicin—testicular cancer	2.3e-05	0.000522	CcSEcCtD
Crizotinib—Vomiting—Doxorubicin—testicular cancer	2.28e-05	0.000517	CcSEcCtD
Crizotinib—Rash—Doxorubicin—testicular cancer	2.26e-05	0.000512	CcSEcCtD
Crizotinib—Dermatitis—Doxorubicin—testicular cancer	2.25e-05	0.000512	CcSEcCtD
Crizotinib—Nausea—Doxorubicin—testicular cancer	2.13e-05	0.000483	CcSEcCtD
Crizotinib—ABCB1—lymph node—testicular cancer	1.78e-05	0.000317	CbGeAlD
Crizotinib—IRAK1—Innate Immune System—KITLG—testicular cancer	1.5e-05	0.000304	CbGpPWpGaD
Crizotinib—SRC—Signaling by EGFR—KIT—testicular cancer	1.49e-05	0.000302	CbGpPWpGaD
Crizotinib—TBK1—Immune System—KITLG—testicular cancer	1.48e-05	0.000299	CbGpPWpGaD
Crizotinib—IKBKE—Immune System—FGFR3—testicular cancer	1.48e-05	0.000299	CbGpPWpGaD
Crizotinib—SRC—Signaling by EGFR in Cancer—KIT—testicular cancer	1.48e-05	0.000299	CbGpPWpGaD
Crizotinib—SRC—Signaling by PDGF—KIT—testicular cancer	1.47e-05	0.000298	CbGpPWpGaD
Crizotinib—RIPK2—Adaptive Immune System—FGFR3—testicular cancer	1.46e-05	0.000296	CbGpPWpGaD
Crizotinib—FGR—Innate Immune System—FGFR3—testicular cancer	1.46e-05	0.000295	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—KITLG—testicular cancer	1.46e-05	0.000295	CbGpPWpGaD
Crizotinib—SRC—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	1.45e-05	0.000294	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—BCL10—testicular cancer	1.45e-05	0.000294	CbGpPWpGaD
Crizotinib—JAK2—Signaling by NGF—FGFR3—testicular cancer	1.44e-05	0.000292	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—H2AFZ—testicular cancer	1.44e-05	0.000291	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—STK11—testicular cancer	1.43e-05	0.000289	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—BCL10—testicular cancer	1.42e-05	0.000288	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—KIT—testicular cancer	1.42e-05	0.000288	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—KITLG—testicular cancer	1.42e-05	0.000287	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—INSL3—testicular cancer	1.41e-05	0.000286	CbGpPWpGaD
Crizotinib—TYK2—Immune System—BCL10—testicular cancer	1.41e-05	0.000285	CbGpPWpGaD
Crizotinib—BLK—Adaptive Immune System—FGFR3—testicular cancer	1.4e-05	0.000284	CbGpPWpGaD
Crizotinib—TYK2—Axon guidance—MMP2—testicular cancer	1.4e-05	0.000283	CbGpPWpGaD
Crizotinib—RIPK2—Innate Immune System—KIT—testicular cancer	1.4e-05	0.000283	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—BCL10—testicular cancer	1.36e-05	0.000276	CbGpPWpGaD
Crizotinib—IKBKE—Immune System—KIT—testicular cancer	1.36e-05	0.000275	CbGpPWpGaD
Crizotinib—CDK7—Gene Expression—H2AFZ—testicular cancer	1.35e-05	0.000273	CbGpPWpGaD
Crizotinib—MAPK7—Immune System—FGFR3—testicular cancer	1.34e-05	0.000272	CbGpPWpGaD
Crizotinib—LIMK1—Immune System—FGFR3—testicular cancer	1.34e-05	0.000272	CbGpPWpGaD
Crizotinib—RIPK2—Adaptive Immune System—KIT—testicular cancer	1.34e-05	0.000272	CbGpPWpGaD
Crizotinib—FGR—Innate Immune System—KIT—testicular cancer	1.34e-05	0.000271	CbGpPWpGaD
Crizotinib—JAK3—Immune System—KITLG—testicular cancer	1.34e-05	0.000271	CbGpPWpGaD
Crizotinib—SRC—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	1.33e-05	0.00027	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	1.33e-05	0.000269	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—KITLG—testicular cancer	1.32e-05	0.000268	CbGpPWpGaD
Crizotinib—JAK2—Signaling by NGF—KIT—testicular cancer	1.32e-05	0.000268	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—H2AFZ—testicular cancer	1.3e-05	0.000263	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—FGFR3—testicular cancer	1.3e-05	0.000263	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—FGFR3—testicular cancer	1.3e-05	0.000263	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—STK11—testicular cancer	1.29e-05	0.000262	CbGpPWpGaD
Crizotinib—BLK—Adaptive Immune System—KIT—testicular cancer	1.29e-05	0.000261	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—H2AFZ—testicular cancer	1.27e-05	0.000258	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—STK11—testicular cancer	1.26e-05	0.000256	CbGpPWpGaD
Crizotinib—LCK—Signaling by NGF—FGFR3—testicular cancer	1.26e-05	0.000255	CbGpPWpGaD
Crizotinib—CDK7—Disease—H2AFZ—testicular cancer	1.25e-05	0.000254	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—INSL3—testicular cancer	1.24e-05	0.000251	CbGpPWpGaD
Crizotinib—LIMK1—Immune System—KIT—testicular cancer	1.23e-05	0.00025	CbGpPWpGaD
Crizotinib—MAPK7—Immune System—KIT—testicular cancer	1.23e-05	0.00025	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—FGFR3—testicular cancer	1.23e-05	0.000249	CbGpPWpGaD
Crizotinib—CYP3A4—Biological oxidations—HPGDS—testicular cancer	1.22e-05	0.000248	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—KITLG—testicular cancer	1.2e-05	0.000242	CbGpPWpGaD
Crizotinib—PTK2—Innate Immune System—FGFR3—testicular cancer	1.19e-05	0.000242	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—KITLG—testicular cancer	1.19e-05	0.000241	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—KIT—testicular cancer	1.19e-05	0.000241	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—KIT—testicular cancer	1.19e-05	0.000241	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—KITLG—testicular cancer	1.18e-05	0.000239	CbGpPWpGaD
Crizotinib—YES1—Innate Immune System—FGFR3—testicular cancer	1.18e-05	0.000238	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—KITLG—testicular cancer	1.18e-05	0.000238	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—KITLG—testicular cancer	1.17e-05	0.000238	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—KITLG—testicular cancer	1.17e-05	0.000237	CbGpPWpGaD
Crizotinib—LCK—Signaling by NGF—KIT—testicular cancer	1.16e-05	0.000234	CbGpPWpGaD
Crizotinib—CDK7—Disease—KITLG—testicular cancer	1.15e-05	0.000234	CbGpPWpGaD
Crizotinib—BLK—Immune System—KITLG—testicular cancer	1.15e-05	0.000232	CbGpPWpGaD
Crizotinib—FGR—Immune System—KITLG—testicular cancer	1.14e-05	0.000231	CbGpPWpGaD
Crizotinib—LYN—Immune System—BCL10—testicular cancer	1.14e-05	0.000231	CbGpPWpGaD
Crizotinib—ABL1—Immune System—BCL10—testicular cancer	1.14e-05	0.00023	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—KITLG—testicular cancer	1.13e-05	0.00023	CbGpPWpGaD
Crizotinib—LYN—Axon guidance—MMP2—testicular cancer	1.13e-05	0.000229	CbGpPWpGaD
Crizotinib—YES1—Adaptive Immune System—FGFR3—testicular cancer	1.13e-05	0.000229	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—KIT—testicular cancer	1.13e-05	0.000229	CbGpPWpGaD
Crizotinib—ABL1—Axon guidance—MMP2—testicular cancer	1.13e-05	0.000228	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—FGFR3—testicular cancer	1.12e-05	0.000228	CbGpPWpGaD
Crizotinib—SRC—Signaling by NGF—FGFR3—testicular cancer	1.12e-05	0.000226	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—FGFR3—testicular cancer	1.12e-05	0.000226	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—KITLG—testicular cancer	1.1e-05	0.000224	CbGpPWpGaD
Crizotinib—PTK2—Developmental Biology—MMP2—testicular cancer	1.1e-05	0.000223	CbGpPWpGaD
Crizotinib—TBK1—Immune System—FGFR3—testicular cancer	1.1e-05	0.000223	CbGpPWpGaD
Crizotinib—PTK2—Innate Immune System—KIT—testicular cancer	1.1e-05	0.000222	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—INSL3—testicular cancer	1.1e-05	0.000222	CbGpPWpGaD
Crizotinib—YES1—Developmental Biology—MMP2—testicular cancer	1.08e-05	0.00022	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—FGFR3—testicular cancer	1.08e-05	0.000219	CbGpPWpGaD
Crizotinib—YES1—Innate Immune System—KIT—testicular cancer	1.08e-05	0.000219	CbGpPWpGaD
Crizotinib—JAK2—Immune System—BCL10—testicular cancer	1.07e-05	0.000216	CbGpPWpGaD
Crizotinib—JAK2—Axon guidance—MMP2—testicular cancer	1.06e-05	0.000215	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—FGFR3—testicular cancer	1.05e-05	0.000213	CbGpPWpGaD
Crizotinib—YES1—Adaptive Immune System—KIT—testicular cancer	1.04e-05	0.00021	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—KIT—testicular cancer	1.03e-05	0.000209	CbGpPWpGaD
Crizotinib—SRC—Signaling by NGF—KIT—testicular cancer	1.02e-05	0.000208	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—KIT—testicular cancer	1.02e-05	0.000208	CbGpPWpGaD
Crizotinib—TBK1—Immune System—KIT—testicular cancer	1.01e-05	0.000204	CbGpPWpGaD
Crizotinib—TYK2—Developmental Biology—MMP2—testicular cancer	9.98e-06	0.000202	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—KIT—testicular cancer	9.95e-06	0.000201	CbGpPWpGaD
Crizotinib—JAK3—Immune System—FGFR3—testicular cancer	9.94e-06	0.000201	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—FGFR3—testicular cancer	9.83e-06	0.000199	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—KITLG—testicular cancer	9.68e-06	0.000196	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—KIT—testicular cancer	9.67e-06	0.000196	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—H2AFZ—testicular cancer	9.4e-06	0.00019	CbGpPWpGaD
Crizotinib—PTK2—Immune System—KITLG—testicular cancer	9.35e-06	0.000189	CbGpPWpGaD
Crizotinib—LCK—Immune System—BCL10—testicular cancer	9.35e-06	0.000189	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—STK11—testicular cancer	9.34e-06	0.000189	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—KITLG—testicular cancer	9.29e-06	0.000188	CbGpPWpGaD
Crizotinib—YES1—Immune System—KITLG—testicular cancer	9.22e-06	0.000187	CbGpPWpGaD
Crizotinib—JAK3—Immune System—KIT—testicular cancer	9.12e-06	0.000185	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—KIT—testicular cancer	9.02e-06	0.000183	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—FGFR3—testicular cancer	8.89e-06	0.00018	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—FGFR3—testicular cancer	8.86e-06	0.000179	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—FGFR3—testicular cancer	8.77e-06	0.000178	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—KITLG—testicular cancer	8.75e-06	0.000177	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—FGFR3—testicular cancer	8.73e-06	0.000177	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—FGFR3—testicular cancer	8.73e-06	0.000177	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—FGFR3—testicular cancer	8.7e-06	0.000176	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—KITLG—testicular cancer	8.64e-06	0.000175	CbGpPWpGaD
Crizotinib—CDK7—Disease—FGFR3—testicular cancer	8.57e-06	0.000174	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—KITLG—testicular cancer	8.57e-06	0.000173	CbGpPWpGaD
Crizotinib—TYK2—Disease—H2AFZ—testicular cancer	8.52e-06	0.000173	CbGpPWpGaD
Crizotinib—BLK—Immune System—FGFR3—testicular cancer	8.52e-06	0.000173	CbGpPWpGaD
Crizotinib—FGR—Immune System—FGFR3—testicular cancer	8.49e-06	0.000172	CbGpPWpGaD
Crizotinib—TYK2—Immune System—KITLG—testicular cancer	8.49e-06	0.000172	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—FGFR3—testicular cancer	8.43e-06	0.000171	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—H2AFZ—testicular cancer	8.37e-06	0.00017	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—STK11—testicular cancer	8.33e-06	0.000169	CbGpPWpGaD
Crizotinib—SRC—Immune System—BCL10—testicular cancer	8.27e-06	0.000168	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—H2AFZ—testicular cancer	8.25e-06	0.000167	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—KITLG—testicular cancer	8.23e-06	0.000167	CbGpPWpGaD
Crizotinib—SRC—Axon guidance—MMP2—testicular cancer	8.22e-06	0.000166	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—FGFR3—testicular cancer	8.21e-06	0.000166	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—STK11—testicular cancer	8.21e-06	0.000166	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—KIT—testicular cancer	8.16e-06	0.000165	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—KIT—testicular cancer	8.13e-06	0.000165	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—MMP2—testicular cancer	8.08e-06	0.000164	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—KIT—testicular cancer	8.06e-06	0.000163	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—MMP2—testicular cancer	8.05e-06	0.000163	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—KIT—testicular cancer	8.02e-06	0.000162	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—KIT—testicular cancer	8.01e-06	0.000162	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—KIT—testicular cancer	7.98e-06	0.000162	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—H2AFZ—testicular cancer	7.9e-06	0.00016	CbGpPWpGaD
Crizotinib—CDK7—Disease—KIT—testicular cancer	7.87e-06	0.000159	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—STK11—testicular cancer	7.85e-06	0.000159	CbGpPWpGaD
Crizotinib—TYK2—Disease—KITLG—testicular cancer	7.84e-06	0.000159	CbGpPWpGaD
Crizotinib—BLK—Immune System—KIT—testicular cancer	7.82e-06	0.000158	CbGpPWpGaD
Crizotinib—FGR—Immune System—KIT—testicular cancer	7.8e-06	0.000158	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—KIT—testicular cancer	7.74e-06	0.000157	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—KITLG—testicular cancer	7.7e-06	0.000156	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—H2AFZ—testicular cancer	7.66e-06	0.000155	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—STK11—testicular cancer	7.62e-06	0.000154	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—KITLG—testicular cancer	7.59e-06	0.000154	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—MMP2—testicular cancer	7.56e-06	0.000153	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—KIT—testicular cancer	7.54e-06	0.000153	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—KITLG—testicular cancer	7.27e-06	0.000147	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—FGFR3—testicular cancer	7.19e-06	0.000146	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—KITLG—testicular cancer	7.05e-06	0.000143	CbGpPWpGaD
Crizotinib—PTK2—Immune System—FGFR3—testicular cancer	6.95e-06	0.000141	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—FGFR3—testicular cancer	6.91e-06	0.00014	CbGpPWpGaD
Crizotinib—LYN—Immune System—KITLG—testicular cancer	6.88e-06	0.000139	CbGpPWpGaD
Crizotinib—YES1—Immune System—FGFR3—testicular cancer	6.85e-06	0.000139	CbGpPWpGaD
Crizotinib—ABL1—Immune System—KITLG—testicular cancer	6.84e-06	0.000139	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—KIT—testicular cancer	6.6e-06	0.000134	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—H2AFZ—testicular cancer	6.57e-06	0.000133	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—STK11—testicular cancer	6.53e-06	0.000132	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—FGFR3—testicular cancer	6.5e-06	0.000132	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—H2AFZ—testicular cancer	6.48e-06	0.000131	CbGpPWpGaD
Crizotinib—JAK2—Disease—H2AFZ—testicular cancer	6.46e-06	0.000131	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—STK11—testicular cancer	6.44e-06	0.000131	CbGpPWpGaD
Crizotinib—JAK2—Immune System—KITLG—testicular cancer	6.43e-06	0.00013	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—FGFR3—testicular cancer	6.42e-06	0.00013	CbGpPWpGaD
Crizotinib—PTK2—Immune System—KIT—testicular cancer	6.38e-06	0.000129	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—FGFR3—testicular cancer	6.37e-06	0.000129	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—KIT—testicular cancer	6.34e-06	0.000128	CbGpPWpGaD
Crizotinib—TYK2—Immune System—FGFR3—testicular cancer	6.31e-06	0.000128	CbGpPWpGaD
Crizotinib—YES1—Immune System—KIT—testicular cancer	6.29e-06	0.000127	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—H2AFZ—testicular cancer	6.15e-06	0.000124	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—FGFR3—testicular cancer	6.11e-06	0.000124	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—STK11—testicular cancer	6.11e-06	0.000124	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—KITLG—testicular cancer	6.05e-06	0.000122	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—KIT—testicular cancer	5.97e-06	0.000121	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—H2AFZ—testicular cancer	5.97e-06	0.000121	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—KITLG—testicular cancer	5.96e-06	0.000121	CbGpPWpGaD
Crizotinib—JAK2—Disease—KITLG—testicular cancer	5.94e-06	0.00012	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—STK11—testicular cancer	5.93e-06	0.00012	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—KIT—testicular cancer	5.9e-06	0.000119	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—MMP2—testicular cancer	5.87e-06	0.000119	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—KIT—testicular cancer	5.85e-06	0.000118	CbGpPWpGaD
Crizotinib—TYK2—Disease—FGFR3—testicular cancer	5.83e-06	0.000118	CbGpPWpGaD
Crizotinib—TYK2—Immune System—KIT—testicular cancer	5.79e-06	0.000117	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—FGFR3—testicular cancer	5.73e-06	0.000116	CbGpPWpGaD
Crizotinib—LCK—Disease—H2AFZ—testicular cancer	5.66e-06	0.000115	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—KITLG—testicular cancer	5.65e-06	0.000115	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—FGFR3—testicular cancer	5.64e-06	0.000114	CbGpPWpGaD
Crizotinib—LCK—Immune System—KITLG—testicular cancer	5.64e-06	0.000114	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—KIT—testicular cancer	5.61e-06	0.000114	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—KITLG—testicular cancer	5.49e-06	0.000111	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—FGFR3—testicular cancer	5.4e-06	0.000109	CbGpPWpGaD
Crizotinib—TYK2—Disease—KIT—testicular cancer	5.35e-06	0.000108	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—KIT—testicular cancer	5.26e-06	0.000106	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—FGFR3—testicular cancer	5.24e-06	0.000106	CbGpPWpGaD
Crizotinib—LCK—Disease—KITLG—testicular cancer	5.2e-06	0.000105	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—KIT—testicular cancer	5.18e-06	0.000105	CbGpPWpGaD
Crizotinib—LYN—Immune System—FGFR3—testicular cancer	5.11e-06	0.000103	CbGpPWpGaD
Crizotinib—ABL1—Immune System—FGFR3—testicular cancer	5.09e-06	0.000103	CbGpPWpGaD
Crizotinib—SRC—Disease—H2AFZ—testicular cancer	5.01e-06	0.000101	CbGpPWpGaD
Crizotinib—SRC—Immune System—KITLG—testicular cancer	4.99e-06	0.000101	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—KIT—testicular cancer	4.96e-06	0.0001	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—H2AFZ—testicular cancer	4.83e-06	9.79e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—KIT—testicular cancer	4.81e-06	9.74e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—STK11—testicular cancer	4.8e-06	9.73e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—FGFR3—testicular cancer	4.78e-06	9.69e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—KIT—testicular cancer	4.69e-06	9.5e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—KIT—testicular cancer	4.67e-06	9.46e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—KITLG—testicular cancer	4.61e-06	9.33e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—H2AFZ—testicular cancer	4.52e-06	9.16e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—HPGDS—testicular cancer	4.5e-06	9.11e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—STK11—testicular cancer	4.5e-06	9.11e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—FGFR3—testicular cancer	4.49e-06	9.1e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—KITLG—testicular cancer	4.45e-06	9e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—FGFR3—testicular cancer	4.43e-06	8.97e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—FGFR3—testicular cancer	4.42e-06	8.94e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—KIT—testicular cancer	4.39e-06	8.89e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—FGFR3—testicular cancer	4.2e-06	8.51e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—FGFR3—testicular cancer	4.19e-06	8.48e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—KITLG—testicular cancer	4.16e-06	8.43e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—KIT—testicular cancer	4.13e-06	8.35e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—FGFR3—testicular cancer	4.08e-06	8.26e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—KIT—testicular cancer	4.07e-06	8.24e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—KIT—testicular cancer	4.05e-06	8.21e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—H2AFZ—testicular cancer	3.96e-06	8.02e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—STK11—testicular cancer	3.94e-06	7.98e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—FGFR3—testicular cancer	3.87e-06	7.83e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—KIT—testicular cancer	3.86e-06	7.81e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—KIT—testicular cancer	3.85e-06	7.79e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—KIT—testicular cancer	3.75e-06	7.59e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—FGFR3—testicular cancer	3.71e-06	7.51e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KITLG—testicular cancer	3.64e-06	7.38e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—KIT—testicular cancer	3.55e-06	7.19e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—H2AFZ—testicular cancer	3.51e-06	7.1e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—STK11—testicular cancer	3.49e-06	7.06e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—FGFR3—testicular cancer	3.42e-06	6.93e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—KIT—testicular cancer	3.4e-06	6.9e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—HPGDS—testicular cancer	3.4e-06	6.88e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—FGFR3—testicular cancer	3.3e-06	6.69e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—STK11—testicular cancer	3.27e-06	6.62e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KITLG—testicular cancer	3.23e-06	6.53e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—KIT—testicular cancer	3.14e-06	6.37e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—FGFR3—testicular cancer	3.09e-06	6.26e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—KIT—testicular cancer	3.03e-06	6.14e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—KIT—testicular cancer	2.84e-06	5.75e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—FGFR3—testicular cancer	2.71e-06	5.48e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KIT—testicular cancer	2.49e-06	5.04e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—STK11—testicular cancer	2.47e-06	5e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FGFR3—testicular cancer	2.4e-06	4.86e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KIT—testicular cancer	2.2e-06	4.46e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—HPGDS—testicular cancer	2.09e-06	4.24e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—STK11—testicular cancer	1.52e-06	3.08e-05	CbGpPWpGaD
